Bone Biologics Corp
For the period ended Dec 31, 2024. Filed Apr 23, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2024 · Filed Apr 23, 2025
Contents
APPENDIX B
SECOND AMENDMENT
TO THE
2015 EQUITY INCENTIVE PLAN
The Bone Biologics 2015 Equity Incentive Plan (the “Plan”) is hereby amended as follows, effective May 30, 2025:
- Section 3(a)(i) of the Plan is hereby amended and restated in its entirety to provide as follows:
“**(i)**Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 30,629,489 (the “Share Reserve”).”
- Section 3(c) of the Plan is hereby amended and restated in its entirety to provide as follows:
“(c) Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 30,629,489 shares of Common Stock.”
B-1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.